David R. Spigel: Breaking down barriers to make clinical trials more accessible for people facing cancer
David R. Spigel, Chief Scientific Officer at Sarah Cannon Research Institute, posted on LinkedIn:
“Last week, the Sarah Cannon Research Institute network and our collaborators came together to amplify the importance of clinical trials and patient-centered research. As we conclude World Cancer Day, I want to reflect on the collaboration and unity seen throughout the past week.
At SCRI, our shared commitment to advancing cancer care means breaking down barriers to make clinical trials more accessible for people facing cancer. For our researchers, we’ve reimagined our operations model to streamline and accelerate drug development, ensuring a faster, more seamless experience that ultimately benefits both patients and providers.
Thank you to everyone who joined this meaningful conversation. Let’s carry this momentum forward.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023